Antigen epitope for exciting human anti-tubercle bacillus protective immunoreaction and its use

Abstract

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

Description

Technical field:

[0001] The present invention relates to the field of molecular immunology, in particular to molecular mimic peptides capable of stimulating the human body's protective immune response against tuberculosis bacilli and their screening methods and uses. Background technique:

[0002] In recent years, tuberculosis (Tuberculosis, TB) has revived on a global scale. According to statistics from the World Health Organization, about one-third of the world's population and about 2 billion people are infected with Mycobacterium tuberculosis (Mtb), with about 9 million new cases each year, and up to 3 million deaths each year. The World Health Organization proposed a "global emergency" (global emergency). It can be seen that the impact and damage caused by tuberculosis to human health and the economy is difficult to simply assess. The characteristics of the epidemic of tuberculosis in my country are: high prevalence, high drug resistance rate, high death rate, high infection...

Examples

Embodiment 1

[0029] 1Materials and methods

[0030] 1.1 Research object

[0031] There were 200 confirmed pulmonary tuberculosis patients, of which 100 were HLA-A*0201 positive and 100 were HLA-A*0201 negative, all of which were examined by radiology and clinical sputum culture. 100 HLA-A*0201 positive patients with other chronic lung diseases were the disease control group, and 100 HLA-A*0201 positive healthy volunteers were the normal control group.

[0032] 1.2 Reagents and kits:

[0033] Lymphocyte Separation Solution Lymphoprep TM Purchased from AXIS-SHIELD, Norway;

[0034] LPS, human recombinant IL-2, DMSO, BFA, β 2 -mg were purchased from Sigma;

[0035] Human recombinant GM-CSF and human recombinant IL-4 were purchased from R&D company;

[0036] RPMI1640 medium and fetal bovine serum were purchased from Gibco; (Sigma);

[0037] FITC-labeled anti-CD3, anti-CD8, anti-HLA.A2 flow cytometric monoclonal antibodies and FITC-labeled antibodies for detecting intracellular factors (IFN-γ, TNF-...

Technical field:

[0001] The present invention relates to the field of molecular immunology, in particular to molecular mimic peptides capable of stimulating the human body's protective immune response against tuberculosis bacilli and their screening methods and uses. Background technique:

[0002] In recent years, tuberculosis (Tuberculosis, TB) has revived on a global scale. According to statistics from the World Health Organization, about one-third of the world's population and about 2 billion people are infected with Mycobacterium tuberculosis (Mtb), with about 9 million new cases each year, and up to 3 million deaths each year. The World Health Organization proposed a "global emergency" (global emergency). It can be seen that the impact and damage caused by tuberculosis to human health and the economy is difficult to simply assess. The characteristics of the epidemic of tuberculosis in my country are: high prevalence, high drug resistance rate, high death rate, high infection...

Examples

Embodiment 1

[0029] 1Materials and methods

[0030] 1.1 Research object

[0031] There were 200 confirmed pulmonary tuberculosis patients, of which 100 were HLA-A*0201 positive and 100 were HLA-A*0201 negative, all of which were examined by radiology and clinical sputum culture. 100 HLA-A*0201 positive patients with other chronic lung diseases were the disease control group, and 100 HLA-A*0201 positive healthy volunteers were the normal control group.

[0032] 1.2 Reagents and kits:

[0033] Lymphocyte Separation Solution Lymphoprep TM Purchased from AXIS-SHIELD, Norway;

[0034] LPS, human recombinant IL-2, DMSO, BFA, β 2 -mg were purchased from Sigma;

[0035] Human recombinant GM-CSF and human recombinant IL-4 were purchased from R&D company;

[0036] RPMI1640 medium and fetal bovine serum were purchased from Gibco; (Sigma);

[0037] FITC-labeled anti-CD3, anti-CD8, anti-HLA.A2 flow cytometric monoclonal antibodies and FITC-labeled antibodies for detecting intracellular factors (IFN-γ, TNF-...

Images